Malignancies in β-thalassemia patients: A single-center experience and a concise review of the literature

International Journal of Laboratory Hematology

Volumn 30, Issue 2, 2008, Pages 167-172

  Benetatos, L ^a   Alymara, V ^a   Vassou, A ^a   Bourantas, K L ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Cancer; Hodgkin disease; Non Hodgkin lymphoma; Seminoma; Thalassemia

Indexed keywords

BLEOMYCIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DACARBAZINE; DEFEROXAMINE; DOXORUBICIN; TRANSFERRIN; VINBLASTINE;

ARTICLE; BETA THALASSEMIA; CANCER RISK; CANCER SUSCEPTIBILITY; CASE REPORT; CHILD; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; IRON BINDING CAPACITY; LIFESPAN; MALE; NONHODGKIN LYMPHOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; SEMINOMA;

ADULT; BETA-THALASSEMIA; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASMS; RADIOTHERAPY, ADJUVANT; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 40549105124     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2007.00929.x     Document Type: Article

References (31)

1. Alymara V., Bourantas D., Chaidos A., Bouranta P., Gouva M., Vassou A., Tzouvara E. Bourantas K.L. (2004) Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. The Hematology Journal 5, 475 479.
2. Atweh G.F., DeSimone J., Saunthararajah Y., Fathallah H., Weinberg R.S., Nagel R.L., Fabry M.E. Adams R.J. (2003) Hemoglobinopathies. Hematology (American Society of Hematology. Education Program), 14 39.
3. Balestrazzi P. Butturini A. (1985) Thalassaemia and Hodgkin lymphoma. Blut 501, 55.
4. Borgna-Pignatti C., Vergine G., Lombardo T., Cappellini M.D., Cianciulli P., Maggio A., Renda D., Lai M.E., Mandas A., Forni G., Piga A. Bisconte M.G. (2004a) Hepatocellular carcinoma in the thalassaemia syndromes. British Journal of Haematology 1241, 114 117.
5. Borgna-Pignatti C., Rugolotto S., De Stefano P., Zhao H., Cappellini M.D., Del Vecchio G.C., Romeo M.A., Forni G.L., Gamberini M.R., Ghilardi R., Piga A. Cnaan A. (2004b) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89, 1187 1193.
6. Bourantas K., Economou G. Georgiou J. (1997) Administration of high doses of recombinant human erythropoietin to patients with beta-thalassemia intermedia: a preliminary trial. European Journal of Haematology 58, 22 25. Erratum in : European Journal of Haematology (1997) 59, 65.
7. Chaidos A., Makis A., Hatzimichael E., Tsiara S., Gouva M., Tzouvara E. Bourantas K.L. (2004) Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. Acta Haematologica 111, 189 195.
8. Chehal A., Loutfi R. Taher A. (2002) Beta-thalassemia intermedia and non-Hodgkin's lymphoma. Hemoglobin 26, 219 225.
9. Dearnaley D., Huddart R. Horwich A. (2001) Regular review: managing testicular cancer. BMJ 322, 1583 1588.
10. Fahey J.L., Rahbar S., Farbstein M.J., Forman S.J., Blume K.G. Beutler E. (1986) Microcytosis in Hodgkin disease associated with unbalanced globin chain synthesis. American Journal of Hematology 23, 123 129.
11. Galanello R. Cao A. (1998) Relationship between genotype and phenotype. Thalassemia intermedia. Annals of the New York Academy of Sciences 850, 325 333.
12. Huang X. (2003) Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutation Research 533, 153 171.
13. Jabr F.I., Aoun E., Yassine H., Azar C. Taher A. (2006) Beta-thalassemia intermedia and Hodgkin lymphoma. American Journal of Hematology 81, 151.
14. Kaloterakis A., Filiotou A., Konstantopoulos K., Rombos Y., Bossinakou I. Hadziyannis S. (2001) Multiple myeloma in sickle cell syndromes. Haematologia 31, 153 159.
15. Kaur P. Basu S. (2005) Transfusion-transmitted infections: existing and emerging pathogens. Journal of Postgraduate Medicine 51, 146 151.
16. Ladis V., Chouliaras G., Berdousi H., Kanavakis E. Kattamis C. (2005) Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Annals of the New York Academy of Sciences 1054, 445 450.
17. Lister T.A. Crowther D. (1990) Staging for Hodgkin's disease. Seminars in Oncology 17, 696 703.
18. Mancuso A., Rigano P., Rend D., Di Salvo V., Borgna Pignatti C., Guddo F., Buccellato A., Nicoli N. Maggio A. (2005) Hepatocellular carcinoma on cirrhosis-free liver in a HCV-infected thalassemic. American Journal of Hematology 78, 158 165.
19. Moschovi M., Psychou F., Menegas D., Tsangaris G.T., Tzortzatou- Stathopoulou F. Nikolaidou P. (2001) Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea. Pediatric Hematology and Oncology 18, 371 376.
20. Naithani R., Chandra J., Bhattacharjee J., Verma P. Narayan S. (2006) Peroxidative stress and antioxidant enzymes in children with beta-thalassemia major. Pediatr Blood Cancer 46, 780 785.
21. Nogova L., Reineke T., Josting A., Muller-Hermelink H.K., Eich H.T., Behringer K., Muller R.P., Diehl V. Engert A. (2005) Lymphocyte-predominant and classical Hodgkin's lymphoma-comparison of outcomes. European Journal of Haematology (Suppl.) 66, 106 110.
22. Otrock Z.K., Shamseddine A.I. Taher A.T. (2006) Non-Hodgkin disease in beta-thalassemia major. American Journal of Hematology 81, 62 64.
23. Pootrakul P., Breuer W., Sametband M., Sirankapracha P., Hershko C. Cabantchik Z.I. (2004) Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 104, 1504 1510.
24. Puntarulo S. (2005) Iron, oxidative stress and human health. Molecular Aspects of Medicine 26, 299 312.
25. Ricchi A., Carta A., Pinna G.M., Cirio E.M., Foddanu M., Terrosu P.F., Pardini S., Fozza C. Longinotti M. (2004) Asymptomatic cardiac lymphoma in a hepatitis C virus-positive thalassemic patient. Italian Heart Journal 5, 302 304.
26. Richardson D.R. (1997) Potential of iron chelators as effective antiproliferative agents. Canadian Journal of Physiology and Pharmacology 75, 1164 1180.
27. Rund D. Rachmilewitz E. (2000) New trends in the treatment of beta-thalassemia. Critical Reviews in Oncology/Hematology 33, 105 118.
28. Rund D. Rachmilewitz E. (2005) Beta-thalassemia. New England Journal of Medicine 353, 1135 1146.
29. Valko M., Izakovic M., Mazur M., Rhodes C.J. Telser J. (2004) Role of oxygen radicals in DNA damage and cancer incidence. Molecular and Cellular Biochemistry 266, 37 56.
30. Voskaridou E., Terpos E., Komninaka V., Eftyhiadis E., Mantzourani M. Loukopoulos D. (2002) Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide. British Journal of Haematology 116, 155 157.
31. Walker E.M. Jr. Walker S.M. (2000) Effects of iron overload on the immune system. Annals of Clinical and Laboratory Science 30, 354 365.